Amolyt Pharma

Amolyt Pharma is building on its teams established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharmas portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors

Hypoparathyroidism,endocrinology,metabolic disease,therapeutic peptides,endocrine disease ,and rare disease

Amolyt pharma operates in the Biotechnology research industry.

Amolyt pharma's revenue is 11m - 100m

Amolyt pharma has 11 - 50 employees.